WallStSmart

Elevance Health Inc (ELV)vsSynopsys Inc (SNPS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 2209% more annual revenue ($200.42B vs $8.68B). SNPS leads profitability with a 8.9% profit margin vs 2.6%. ELV appears more attractively valued with a PEG of 1.47. ELV earns a higher WallStSmart Score of 56/100 (C).

ELV

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 5.5Value: 6.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.66

SNPS

Hold

47

out of 100

Grade: D+

Growth: 6.7Profit: 5.0Value: 3.0Quality: 4.5
Piotroski: 1/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELVUndervalued (+4.5%)

Margin of Safety

+4.5%

Fair Value

$416.35

Current Price

$415.53

$0.82 discount

UndervaluedFair: $416.35Overvalued

Intrinsic value data unavailable for SNPS.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$87.28B9/10

Large-cap with strong market position

P/E RatioValuation
17.0x8/10

Attractively priced relative to earnings

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$4.10B8/10

Generating 4.1B in free cash flow

SNPS3 strengths · Avg: 9.0/10
Revenue GrowthGrowth
41.9%10/10

Revenue surging 41.9% year-over-year

Market CapQuality
$85.86B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

Areas to Watch

ELV3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

EPS GrowthGrowth
-16.8%2/10

Earnings declined 16.8%

SNPS4 concerns · Avg: 2.5/10
Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

PEG RatioValuation
2.882/10

Expensive relative to growth rate

P/E RatioValuation
104.3x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : SNPS

The strongest argument for SNPS centers on Revenue Growth, Market Cap, Price/Book. Revenue growth of 41.9% demonstrates continued momentum.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, EPS Growth. Thin 2.6% margins leave little buffer for downturns.

Bear Case : SNPS

The primary concerns for SNPS are Return on Equity, Piotroski F-Score, PEG Ratio. A P/E of 104.3x leaves little room for execution misses.

Key Dynamics to Monitor

ELV profiles as a value stock while SNPS is a hypergrowth play — different risk/reward profiles.

SNPS carries more volatility with a beta of 1.21 — expect wider price swings.

SNPS is growing revenue faster at 41.9% — sustainability is the question.

ELV generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

ELV scores higher overall (56/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Synopsys Inc

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Synopsys is an American electronic design automation company that focuses on silicon design and verification, silicon intellectual property and software security and quality. Products include logic synthesis, behavioral synthesis, place and route, static timing analysis, formal verification, hardware description language (SystemC, SystemVerilog/Verilog, VHDL) simulators, and transistor-level circuit simulation.

Visit Website →

Want to dig deeper into these stocks?